Stock Markets February 25, 2026

Casey Means to Testify Before Senate Panel in Delayed Surgeon General Confirmation

Trump nominee and ally of Health Secretary Robert F. Kennedy Jr. faces a long-awaited hearing after an earlier postponement prompted by childbirth

By Hana Yamamoto
Casey Means to Testify Before Senate Panel in Delayed Surgeon General Confirmation

Casey Means, President Donald Trump’s nominee for U.S. surgeon general and an ally of Health Secretary Robert F. Kennedy Jr., will appear before the Senate Health, Education, Labor, and Pensions Committee on Wednesday in a confirmation hearing that was postponed from October. Means, 38, has close ties to Kennedy and to her brother, Calley Means, a Trump administration food policy adviser. The nomination is Trump’s second for the role following the withdrawal of Janette Nesheiwat in May and has drawn criticism from both far-right activists and establishment figures over Means’ medical positions and public statements.

Key Points

  • Casey Means, 38, is scheduled to appear before the Senate Health, Education, Labor, and Pensions Committee on Wednesday for a long-delayed confirmation hearing.
  • Means is a close ally of Health Secretary Robert F. Kennedy Jr. and, along with her brother Calley Means - a Trump administration food policy adviser - supports the "Make America Healthy Again" initiative; sectors impacted include health care, food policy, and health technology.
  • The nomination is Trump’s second for surgeon general after Janette Nesheiwat withdrew in May; Means has faced criticism from far-right activists and establishment figures over her public health positions.

WASHINGTON, Feb 25 - Casey Means, the 38-year-old nominated by President Donald Trump to serve as U.S. surgeon general and a close ally of Health Secretary Robert F. Kennedy Jr., is scheduled to appear on Wednesday before the Senate Health, Education, Labor, and Pensions Committee for a confirmation hearing that has been delayed since October.

The hearing had been set for October but was rescheduled after Means went into labor at 40 weeks of pregnancy. If confirmed, Means would assume the duties of the nation’s doctor, providing guidance to Americans on evidence-based practices intended to reduce the risk of illness and injury.

Means and her brother, Calley Means - who serves as a Trump administration adviser on food policy - are described as close allies of Kennedy and as vocal supporters of his "Make America Healthy Again" initiative. The nominee’s ties to administration policy figures and family links to food policy advising have been highlighted in materials surrounding the nomination process.

This nomination marks President Trump’s second selection for the surgeon general post after his initial nominee, Janette Nesheiwat, withdrew in May. Means’ candidacy has encountered opposition from various quarters, including far-right activists such as Laura Loomer and some establishment voices who have raised concerns about her views on certain health topics.

Critics have pointed to several public positions and statements by Means. Among these are her advocacy for the consumption of raw milk, her repeated amplification of claims by Kennedy that link vaccines to autism - claims that have been described in the record as unscientific - and her criticism of the use of birth control pills.

In prepared testimony filed in October, Means, identified as both a medical doctor and a wellness influencer, said she has treated thousands of patients over 15 years across clinic settings, operating rooms, and in her private practice. As of the time immediately before the scheduled Wednesday session, no updated testimony had been posted on the committee’s website.

Means graduated from Stanford University School of Medicine but left her surgical residency before its completion. Her Oregon medical license is listed as "inactive," a status she has described as voluntary because she is not currently practicing medicine.

She is a co-founder of Levels, a health-tech app, and holds shares in Truemed, a business owned by her brother that assists patients in obtaining tax advantages for advanced health treatments. In filings with the Office of Government Ethics, Means has pledged to resign from Levels and to divest her financial interests in both companies if she is confirmed as surgeon general.

At an FDA event on Tuesday, Health Secretary Robert F. Kennedy Jr. praised Means, saying she has "an extraordinary capacity to communicate to the American public" and expressed his belief that she would be confirmed. "We’ve been waiting for a long time for Dr. Means to come on board," he said.


Context for markets and policy observers

  • The confirmation process touches on federal health leadership and could influence public health messaging and regulatory focus.
  • Connections to food policy and health-tech entrepreneurship link the nomination to sectors including health care, food policy regulation, and health technology.

Risks

  • Political and public scrutiny stemming from Means’ past statements on raw milk consumption, vaccine-autism claims, and birth control pills could complicate confirmation and affect public confidence in federal health messaging - this risk impacts public health communications and related regulatory sectors.
  • Potential conflicts of interest noted in Means’ holdings in Levels and shares in Truemed, and her pledge to divest and resign if confirmed, create uncertainty around timelines and implementation of any required divestitures - relevant to health-tech and healthcare services investors.
  • The absence of updated testimony on the committee’s website ahead of the hearing limits visibility into any new information or clarifications Means might provide, leaving senators and markets with incomplete public materials prior to the session - this creates procedural uncertainty for stakeholders monitoring the confirmation.

More from Stock Markets

Premarket Movers: Nvidia Inches Up as Several U.S. Stocks React to Earnings and Forecasts Feb 25, 2026 Morgan Stanley Highlights European Ad Agencies With AI Strengths Feb 25, 2026 Novartis to add Texas radioligand therapy plant, expanding U.S. manufacturing network Feb 25, 2026 Driven Brands shares plunge after company delays results and moves to restate past financials Feb 25, 2026 Goldman Says Near-Term AI Disruption Fears Hard to Refute as Capex Drives Market Volatility Feb 25, 2026